CCI to probe five pharma firms

Complaint has been filed against the five entities for 'engaging in anti-competition practices' in granting stockist licence for medicines in Himachal Pradesh

BS Reporter New Delhi
Last Updated : May 10 2013 | 2:22 AM IST
The Competition Commission of India (CCI) has directed its Director General (Investigations) to initiate a probe against five entities, including pharma major Cipla, on charges of anti-competitive practices.

The five entities include three pharmaceutical companies — drug major Cipla, FDC and Macleods Pharmaceuticals — as well as the Himachal Pradesh Society of Chemists & Druggist Alliance and its president Sanjeev Pandit.

The move has been triggered by a complaint from Rohit Medical store, alleging anti-competitive practices by the five entities in granting stockist licence for medicines in Himachal Pradesh.

Also Read

“After giving our thoughtful consideration on the matter, the Commission is of the opinion that there exists a prima facie case to direct the Director General to carry out an investigation into the matter,” the competition watchdog said in a recent order.

After examining the complaint, the regulator observed that the Himachal Pradesh Society of Chemist & Druggist Alliance appears to be controlling and regulating the appointment of stockist-ship of each and every pharmaceutical company in the state. “The evidence placed on record by the informant shows that no one can be appointed as the stockist of any pharmaceutical company in the state of Himachal Pradesh without the No Objection Certificate (NOC) of Opposite Party No. 5 (Himachal Pradesh Society of Chemist & Druggist Alliance) association,” the CCI order said.

It further said that from examination of facts and circumstances, it appears that the conduct of the association in making it compulsory for the complainant to obtain a NOC before appointment as stockist of the three pharma companies, is in violation of the Competition Act.

The complaint alleged that it was not being granted stockist-ship of Macleods Pharmaceutical, FDC and Cipla due to the condition imposed to obtain a NOC from the chemists association.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 10 2013 | 12:43 AM IST

Next Story